Obstructive sleep apnoea with obesity — indication assessment

§1Assessment

§1.1Definition

Recurrent upper-airway obstruction during sleep producing apnoeas and hypopnoeas, graded by the apnoea–hypopnoea index on polysomnography.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

1. Change in apnoea–hypopnoea index (events/hour)
2. Proportion achieving disease remission or mild disease
3. Change in Epworth Sleepiness Scale
4. Change in systolic blood pressure

§1.3State of the evidence

The Institute assesses 3 compounds in this indication, drawing on 13 trial records and 3 evidence syntheses. ^[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PMID 35658024
2. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023;402(10402):613–626. doi:10.1016/S0140-6736(23)01200-X · PMID 37385275

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.